Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
Active, not recruiting · Phase 1, Phase 2 · NCT03069469
Conditions: Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Tenosynovial Giant Cell Tumor, Diffuse
At a glance
- Research payments reported, 2025
- $701,393
- U.S. investigators named
- 11
- Sites paid
- 16
- Planned or actual enrollment
- 120
About the trial
- Sponsor
- Deciphera Pharmaceuticals, LLC
- Tested
- Vimseltinib (drug)
- Dates
- Started 2017-02-16; completion 2028-08
- Results posted
- Not yet
This is a multicenter, open-label Phase 1/2 study of vimseltinib in patients with malignant solid tumors and tenosynovial giant cell tumor (TGCT). There will be 2 distinct parts in this study: Dose Escalation (Phase 1) and Expansion (Phase 2). Phase 1 will enroll both malignant solid tumor and TGCT patients. Phase 2 will comprise two cohorts (Cohort A and Cohort B) and will only enroll TGCT patients.
From ClinicalTrials.gov, last updated 2026-06-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Deciphera Pharmaceuticals Inc. reported $701,393 in research payments for this study in 2025 (106 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Kristen N. Ganjoo, MD Medical Oncology · Stanford, CA
- Robert L. Randall, MD Orthopedic Surgery · Sacramento, CA
- Breelyn A. Wilky, MD Hematology & Oncology · Aurora, CO
- Gina Z. D'amato, MD Hematology & Oncology · Atlanta, GA
- Benjamin C. Powers, MD Hematology & Oncology · Overland Park, KS
- Andrew J. Wagner, M.D. Hematology & Oncology · Boston, MA
- William D. Tap, MD Hematology & Oncology · New York, NY
- Gabriel R. Tinoco Suarez, M.D. Medical Oncology · Columbus, OH
- Elizabeth T. Loggers, M.D., PH.D. Medical Oncology · Portland, OR
- Christopher W. Ryan, MD Medical Oncology · Portland, OR
- Vinod Ravi, MD Medical Oncology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Regents of the University of Colorado $162,802
- Ohsu Hospital and Clinics, OR $124,520
- Memorial Sloan Kettering Cancer Center $97,676
- The Board of Trustees of the Leland Stanford Junior University $94,714
- The Ohio State University $70,948
- University of Miami $46,340
- Ut MD Anderson Cancer Center $39,907
- University of Kansas Medical Center Research Institute Inc $21,746
- Dana-Farberpartners Cancercare Inc $20,138
- University of California Davis Medical Center, CA $15,170
- Dana-Farbermass General Brigham Cancer Center Inc $3,650
- The Regents of the University of California $1,620
- University of Colorado - Denver $695
- University of Washington Medical Ctr, WA $597
- Rutgers the State University $435
- Oregon Health & Science University $435
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.